Merck Ups Marketing Spend For Januvia And Gardasil As Competitors Stumble
Executive Summary
Merck's decision to step up marketing spend for two of its new products, the DPP-4 inhibitor Januvia for diabetes and the human papilloma virus vaccine Gardasil,may reflect an effort to take advantage of delays in the launches of potential competitor products
You may also be interested in...
Merck Halts Gardasil Lobbying Efforts Following Discussions With ACIP, AAP
Merck decided to halt lobbying efforts for state legislation requiring vaccination with its human papilloma virus vaccine Gardasil for school entry following discussions with third party stakeholders, including CDC's Advisory Committee on Immunization Practices and the American Academy of Pediatrics, the company said
Merck Halts Gardasil Lobbying Efforts Following Discussions With ACIP, AAP
Merck decided to halt lobbying efforts for state legislation requiring vaccination with its human papilloma virus vaccine Gardasil for school entry following discussions with third party stakeholders, including CDC's Advisory Committee on Immunization Practices and the American Academy of Pediatrics, the company said
Gardasil Reimbursement Issues To Be Resolved In Early 2007, Merck Says
Merck expects reimbursement issues for its human papillomavirus vaccine Gardasil to be resolved by early 2007, Merck Vaccines President Margaret McGlynn said Dec. 12